YTTERBIUM YB 169 DTPA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for YTTERBIUM YB 169 DTPA (YTTERBIUM YB 169 DTPA).
Ytterbium Yb 169 DTPA is a radiopharmaceutical that emits gamma radiation. After administration, it distributes in the extracellular fluid and is cleared by glomerular filtration. Its mechanism of action is based on physical decay emission of photons for imaging, with no pharmacological effect.
| Metabolism | Not metabolized; cleared by glomerular filtration without biotransformation. |
| Excretion | Renal: >90% unchanged; biliary/fecal: <10% |
| Half-life | Terminal: 25-50 days (effective half-life due to physical decay of Yb-169); clinical context: imaging agent for cisternography, half-life reflects biological clearance with physical decay (T1/2 physical: 32 days) |
| Protein binding | Negligible (<5%) |
| Volume of Distribution | Vd: 0.15-0.25 L/kg (confined to extracellular space and CSF) |
| Bioavailability | Intrathecal: 100% (as administered); IV: 100% |
| Onset of Action | Intrathecal: immediate (distribution within CSF) within minutes; IV: rapid distribution within 1-2 hours |
| Duration of Action | Intrathecal: imaging adequate for 24-48 hours; IV: imaging window 1-4 hours post-injection |
| Molecular Weight | 497 |
No standard therapeutic dosing; used as a diagnostic radiopharmaceutical. Typical adult activity: 37-111 MBq (1-3 mCi) intravenous injection for cisternography or CSF shunt evaluation.
| Dosage form | INJECTABLE |
| Renal impairment | No specific GFR-based dose modifications established. Use with caution in severe renal impairment due to potential altered clearance; consider minimizing radiation exposure. |
| Liver impairment | No specific Child-Pugh based modifications. Primarily renally cleared; hepatic dysfunction unlikely to require dose adjustment. |
| Pediatric use | Weight-based: 0.1-0.2 mCi/kg (3.7-7.4 MBq/kg) intravenously, minimum dose to achieve adequate imaging; follow institutional pediatric radiopharmaceutical dosing guidelines. |
| Geriatric use | No specific elderly dose adjustments; consider age-related decline in renal function and use minimal effective activity to reduce radiation exposure. |
| 1st trimester | Radiopharmaceutical; use only if potential benefit justifies risk; fetal radiation exposure may cause harm; consider alternative imaging modalities. |
| 2nd trimester | Radiopharmaceutical; use only if potential benefit justifies risk; fetal radiation exposure may cause harm; consider alternative imaging modalities. |
| 3rd trimester | Radiopharmaceutical; use only if potential benefit justifies risk; fetal radiation exposure may cause harm; consider alternative imaging modalities. |
Clinical note
Comprehensive clinical and safety monograph for YTTERBIUM YB 169 DTPA (YTTERBIUM YB 169 DTPA).
| Placental transfer | Ytterbium Yb 169 DTPA is a small chelate (molecular weight ~497 Da) that crosses the placenta; fetal radiation exposure occurs. |
| Breastfeeding | Discontinue breastfeeding temporarily; advise pumping and discarding milk for at least 24 hours after administration to minimize infant exposure to radioactivity. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to ytterbium or DTPAPregnancy (unless benefit outweighs risk)Breastfeeding without appropriate interruption
| Precautions | Radiation exposure risk; use only when necessary, Consider cumulative radiation dose in repeated studies, Allergic reactions possible but rare, Pregnancy and lactation: use only if benefit outweighs risk |
| Food/Dietary | No specific food interactions. Maintain adequate hydration before and after administration. |
| Clinical Pearls |
Loading safety data…
| Lactation Rating | L4 (Hazardous) |
| Teratogenic Risk | Ytterbium Yb 169 DTPA is a radiopharmaceutical. Ionizing radiation exposure during pregnancy is associated with increased risks of fetal malformations, growth restriction, and carcinogenesis. The first trimester (organogenesis) poses the highest risk for teratogenesis; second and third trimester risks include growth impairment and neurodevelopmental effects. The absorbed dose to the fetus depends on maternal dose and radiopharmaceutical kinetics. |
| Fetal Monitoring | Monitor maternal thyroid function (due to potential radioiodine uptake in thyroid) and radiation exposure via dosimetry. Assess fetal dose using standard MIRD methods; consider alternative imaging modalities if possible. Monitor for signs of maternal hypersensitivity reactions. Follow institutional radiation safety protocols. |
| Fertility Effects | No specific data on Yb-169 DTPA and fertility. Ionizing radiation at diagnostic doses (typically <50 mSv) is unlikely to cause permanent fertility impairment. However, animal studies suggest potential for ovarian damage and impaired spermatogenesis at high doses; clinical relevance at diagnostic levels is minimal. |
| Ytterbium Yb 169 DTPA is a radiopharmaceutical used for cisternography to evaluate CSF flow dynamics. Ensure patient is well-hydrated to promote renal clearance. Use aseptic technique during intrathecal administration. Monitor for signs of radiotracer extravasation or CSF leak. Contraindicated in patients with known hypersensitivity to DTPA or ytterbium. |
| Patient Advice | This medication is a radioactive tracer used to evaluate cerebrospinal fluid flow. · You will receive an injection into your lower back (lumbar puncture). · Drink plenty of fluids before and after the procedure to help eliminate the tracer. · Inform your doctor if you are pregnant, breastfeeding, or have any allergies. · Minimize close contact with pregnant women and children for 24 hours after the scan. · The radiation exposure is low and benefits outweigh risks. |